NVS catalysts
Catalysts and events linked to NVS, newest first.
NVS stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth 2026-09-16 · Up | Kymriah revenue runway expansion across hematologic indications | Novartis Kymriah listed as key driver in ALL and lymphoma market expansion. | Not recorded |
| Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M 2026-09-05 · Down | pipeline net present value reduction | Phase 3 HORIZON trial for pelacarsen failed to meet primary endpoint of reducing cardiovascular events. | Not recorded |
| Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint 2026-09-05 · Down | loss of projected late-stage cardiovascular drug franchise revenue | Phase 3 HORIZON trial failed primary endpoint of reducing cardiovascular events. | Not recorded |
| Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint 2026-09-05 · Down | cardiovascular pipeline revenue write-down | Phase 3 HORIZON trial for pelacarsen failed primary endpoint | Not recorded |
| Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial 2026-09-01 · Up | commercial pipeline expansion and regulatory submission milestones | Source explicitly reports Phase III trial superiority over teriflunomide for remibrutinib. | Not recorded |
| Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis 2026-09-01 · Up | neurology pipeline commercialization derisking | Positive Phase III REMODEL-1 and REMODEL-2 trial readouts for remibrutinib. | Not recorded |
| Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials 2026-09-01 · Up | commercial pipeline expansion via Phase III BTK inhibitor superiority | Novartis announced positive Phase III REMODEL-1/-2 trial results for remibrutinib in RMS. | Not recorded |
Do these developments change your position?
Review NVS alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointNVS
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS-11.45%
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS RPRX-11.45%
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary EndpointNVS RPRX
- 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS TrialNVS
- 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS TrialsNVS
- 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS TrialsNVS
- 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS TrialNVS
- 2026-09-01Novartis Reports Positive Phase III Results for Remibrutinib in Multiple SclerosisNVS
- 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS TrialsNVS
- 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS TrialNVS
- 2026-09-01Novartis Reports Positive Phase III Results for Remibrutinib in Multiple SclerosisNVS
- 2026-07-17FDA Grants Traditional Approval to Novartis Fabhalta for IgAN Treatment → Bullish NVSNVS
- 2026-07-17FDA Grants Traditional Approval to Novartis Fabhalta for IgAN Kidney Disease → Bullish NVSNVS
- 2026-07-17FDA Grants Traditional Approval to Novartis Fabhalta for IgAN TreatmentNVS
- 2026-07-17FDA Grants Traditional Approval to Novartis Fabhalta for IgAN Kidney DiseaseNVS
- 2026-07-17FDA Grants Traditional Approval to Novartis Fabhalta for IgAN TreatmentNVS
- 2026-07-17FDA Grants Traditional Approval to Novartis Fabhalta for IgAN Kidney DiseaseNVS
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 Billion in Oncology PushNVS
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS XBI-3.40%
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS XBI-3.40%
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 BillionNVS
- 2026-07-06Novartis to Acquire Myricx Bio for Up to $1.5 Billion in Oncology ExpansionNVS
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.